Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**Cynata Therapeutics Limited**
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	**Dr Kilian Kelly**
Date of last notice	**1 April 2025**

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. Tamara Kelly (Wife) 3. Tamara Kelly & Kilian Kelly <Kelly S/F A/C>
Date of change	3 November 2026
No. of securities held prior to change	1. 477,373 ordinary shares 2,000,000 unlisted options exercisable at $0.176, exp 30/06/2028 2. 231,167 ordinary shares 750,000 unlisted options exercisable at $0.185, exp 20/11/2028 3. 88,888 ordinary shares
Class	Ordinary shares Unlisted options exercisable at $0.02, exp 3 May 2029
Number acquired	1. 179,015 ordinary shares 59,672 unlisted options exercisable at $0.02, exp 3 May 2029 2. 86,688 ordinary shares 28,896 unlisted options exercisable at $0.02, exp 3 May 2029
Number disposed	-

+ See chapter 19 for defined terms.

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	$2,657.03
No. of securities held after change	1. 656,388 ordinary shares 2,000,000 unlisted options exercisable at $0.176, exp 30/06/2028 59,672 unlisted options exercisable at $0.02, exp 3 May 2029 2. 317,855 ordinary shares 750,000 unlisted options exercisable at $0.185, exp 20/11/2028 28,896 unlisted options exercisable at $0.02, exp 3 May 2029 3. 88,888 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take-up of Entitlement Offer.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.